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Background: Protection against hepatitis B disease after
immunization is considered as relying on both the persis-
tence of protective serum antibodies and the ability of the
immune system to mount an anamnestic response when
rechallenged with the hepatitis B virus (HBV). Hexava-
lent DTPa-HBV-IPV/Hib vaccine (Infanrix hexaTM) has been
found to induce comparable seroprotective antibody levels
against hepatitis B as monovalent hepatitis B vaccines in the
short-term, and this study evaluated the long-term immune
memory towards HBV in children aged 4—5 years.
Methods: Open-label study [106789] conducted in 27
centres in Germany, enrolling children aged 4—5 years previ-
ously primed and boosted in routine clinical practice with 4
doses of DTPa-HBV-IPV/Hib vaccine. All subjects received a
single challenge dose of monovalent paediatric HBV vaccine
(EngerixTM-B Kinder; GSK Biologicals). Blood samples were
collected before and one month after vaccination. Anti-
HBs antibodies were measured using ELISA; a concentration
≥10mIU/ml was considered seroprotective.
Results: A total of 301 subjects were vaccinated, of whom
286 were included in the ATP cohort for immunogenicity.
Prior to challenge, 85.3% of subjects had anti-HBs antibod-
ies ≥10mIU/ml and 47.0% of subjects had concentrations
≥100mIU/ml. One month after the challenge, the percent-
ages of subjects increased to 98.3% and 95.8%, respectively.
Anti-HBs antibody Geometric Mean Concentrations rose 100-
fold from 88.7 to 8711.8mIU/ml. The HBV challenge vaccine
was well tolerated and no serious adverse events were
reported.
Conclusion: Primary and booster vaccination with Infan-
rix hexaTM in routine clinical practice induces long-term
seroprotection against hepatitis B and immune memory as
demonstrated by the strong response to HBV challenge.
doi:10.1016/j.ijid.2008.05.194
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Background: The introduction of oral live attenuated
human rotavirus vaccine RIX4414 (RotarixTM, GSK Bio-
logicals) into childhood immunisation schedules can be
facilitated by concomitant administration with routine
diphtheria-tetanus-whole cell pertussis (DTPw) vaccine
combinations. This multicentre trial (104021) assessed the
impact of co-administering RIX4414 vaccine on the immune
response to primary vaccination with two formulations of
DTPw-hepatitis B [DTPw-HBV (ZilbrixTM or TritanrixTM); GSK
Biologicals].
Methods: Healthy infants 11—17 weeks of age were
randomised to receive one of the following vaccination reg-
imens at 3, 4.5 and 6 months of age: RIX4414 vaccine
(3 and 4.5 months) + DTPw-HBV (ZilbrixTM or TritanrixTM);
RIX4414 placebo (3 and 4.5 months) + DTPw-HBV (ZilbrixTM
or TritanrixTM); separate DTPw (Triple AntigenTM; CSL) +HBV
(EngerixTM-B; GSK Biologicals) vaccines. Oral polio vac-
cine was administered concomitantly to all children. Blood
samples for immunogenicity analysis were obtained before
vaccination and one month after the third dose of DTPw
vaccine (Month 7). Solicited adverse events were recorded
on days 0—7 post-vaccination, unsolicited adverse events on
days 0—30 and serious adverse events throughout the entire
study.
Results: 308 subjects were enrolled and vaccinated,
of whom 302 and 254 were included in the ATP cohorts
for safety and immunogenicity, respectively. One month
after the third primary vaccination dose, (2.5 months
after the second RIX4414 dose), anti-rotavirus seroconver-
sion rates70.0—74.5% were seen in the 2 groups receiving
RIX4414. In the groups receiving DTPw-HBV combinations,
seroprotection against diphtheria, tetanus, hepatitis B,
poliovirus types 1, 2 and 3 and vaccine response to B. per-
tussis was seen in 100%, 100%, 100%, ≥97.3% and ≥96.2%
of subjects, respectively. No signiﬁcant increase in the
incidence of solicited adverse events was observed with co-
administration of the RIX4414 vaccine. All vaccine regimens
showed similar reactogenicity and safety proﬁle.
Conclusion: Co-administration of neither RIX4414
(RotarixTM) nor DTPw-HBV vaccines impacted on the
immune response of the other vaccine.
doi:10.1016/j.ijid.2008.05.195
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Campylobacter enterocolitis in Children: A Prospective
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Objective: To evaluate the efﬁcacy of a single oral
azithromycin dose vs. standard oral erythromycin regimen
or no antibiotic for Campylobacter enterocolits in children
≤12 years of age.
Methods: Randomized parallel group assessor-blind trial.
Patients (N = 120) were enrolled ≤48 hours since disease
onset to receive erythromycin 50mg/kg/day over 5 days,
single-dose azithromycin 20mg/kg or 30mg/kg, or no
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antibiotic (no treatment-control) (1:1:1:1). Antibiotics were
commenced 8—10 hours after enrollment. Patients were
assessed in 24-hour intervals over 6 days.
Results: In the intent-to-treat analysis, Campylobac-
ter eradication was achieved in 20/30 controls and
in all antibiotic-treated patients. Incidence of clinical
cure during the observed period was 15/30 in the con-
trol, 14/30 in the erythromycin, 20/30 in the lower
and 25/30 in the higher azithromycin dose group. With
adjustment for age, sex, baseline symptom score and
disease duration before enrollment, only azithromycin
30mg/kg was superior to no treatment: incidence ratio
(IR) = 1.76 (95% CI 1.11—2.87). It was also superior to ery-
thromycin (IR = 1.80, 97.5% CI 1.13—2.84). Regarding time
to clinical cure, only azithromycin 30mg/kg was supe-
rior to no treatment: adjusted hazard ratio (HR = 3.80,
95% CI 1.97—7.32). It was also superior to erythromycin
(HR = 4.17, 97.5% CI 1.91—9.09). All antibiotics improved
(p < 0.05) symptom score reduction over time, most promi-
nently azithromycin 30mg/kg, which was also superior to
erythromycin (p < 0.001). All treatments were well toler-
ated.
Conclusion: Single azithromycin 30mg/kg administration
early after disease onset effectively eradicates the pathogen
and accelerates clinical cure in childhood Campylobacter
enterocolitis. It is clinically superior to an early commenced
5-day erythromycin regimen.
doi:10.1016/j.ijid.2008.05.196
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Chronic Osteomyelitis Mimicking Metastatic Disease
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Lower back pain is an extremely rare chief complaint
in the pediatric population, being more common in adoles-
cents. This ﬁnding is usually associated with acute injuries;
including infections and malignancy as presumptive diag-
noses.
Objective: To consider differential diagnosis in a pedi-
atric patient with lower back pain. To describe a case of
osteomyelitis of infrequent location referred to a pediatric
tertiary care center in Buenos Aires, Argentina.
Case: 16 yo previously healthy Paraguayan male who
presents with progressive lower back pain associated with
intermittent fever. He was initially admitted in an outside
facility in Paraguay, where initial diagnostic studies (includ-
ing CBC, UA and CXR) did not reveal abnormal results. He
was treated with a third-generation cephalosporin for ﬁve
days, with resolution of the fever. Back pain was unrespon-
sive to antimicrobial therapy and to NSAID. After being 14
days afebrile patient developed fever again which prompted
his referral to our institution.
On admission he presented leukocytosis, increased acute
phase reactants and Spine X ray and Spine CT showing a
lesion at the L5 level, with decreased height of the vertebral
body as well as decreased intervertebral space in between
L4 and L5. Chest CT was positive for disseminated nodular
lesions predominantly located in the right lung.
Due to concern for oncologic etiology (Ewing’s Sarcoma)
or infection, further workup was performed, including:
- -Bone scan (scintigraphy): increased uptake in the right
femoral diaphysis, L4 and L5 vertebral bodies
- -Spine MRI: lesion evident in L5-S1without compromise of
the vertebral disc
- -Bone biopsy (vertebral body).
Pathology report was consistent with Chronic Osteomyeli-
tis with super-imposed acute process without evidence of
malignancy. Bone tissue culture and blood cultures were pos-
itive for methicillin-resistant Staphylococcus aureus (MRSA).
Patient received 4 weeks of IV antibiotics with clinical,
biochemical and radiologic improvement.
Conclusion: Speciﬁc lesions account for 85% of children
with lower back pain, of which 20% are infectious or onco-
logic in etiology.
doi:10.1016/j.ijid.2008.05.197
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Background: Evidence suggests that the world-wide inci-
dence of childhood empyema is increasing. The reason is
unknown but may be related to Pneumococcal vaccination
and the increase in prevelance of Streptococcus pneumo-
niae Serotype 1. This study aims to determine the causative
bacterial pathogens andmanagement in childhood empyema
across Australia.
Methods: Children with empyema presenting to 13 hos-
pitals across Australia have been enrolled since March 2007
as part of a 2 year prospective study. Clinical data and blood
and pleural ﬂuid culture results were recorded.
Results: Thirty eight subjects have been recruited, age
4.64 (0.42 to 13) years (median (range)), 21 female. Of
35 blood cultures 8(22.9%) were positive: Streptococcus
pneumoniae, n = 3(37.5%); Streptococcus pyogenes, n = 1
(12.5%); Haemophilus inﬂuenzae, n = 1 (12.5%); Staphylo-
coccus aureus, n = 1 (12.5%); Neisseria meningitides (type
C), n = 1 (12.5%); and coagulase negative Staphylococ-
cus, n = 1 (12.5%). Thirty two pleural ﬂuid samples were
cultured of which 15 (46.9%)were culture positive: Strepto-
coccus pyogenes, n = 6 (40.0%); Staphylococcus aureus, n = 3
(20.0%), Streptococcus pneumoniae n = 2 (13.3%); MRSA,
n = 2 (13.3%); Pseudomonas species, n = 1 (7.1%); Bacillus
cereus, n = 1 (6.7%). 1 subject had Streptococcus pyo-
genes in both blood and pleural ﬂuid; 1 subject had
Streptococcus pneumoniae in blood and Bacillus cereus
in pleural ﬂuid; 1 subject had Staphylococcus aureus in
